Rezolute, Inc. - Common Stock — Filings & Documents (NASDAQ:RZLT) — Page 25 | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

2011

Quarterly report, Q1 FY2012

Rezolute, Inc. quarterly report, Q1 FY2012

Annual report, Q2 FY2011

Rezolute, Inc. annual report, Q2 FY2011

News

This NetApp Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Lake Street Maintains Buy on Rezolute, Raises Price Target to $12

Citizens Maintains Market Outperform on Rezolute, Raises Price Target to $15

This Boyd Gaming Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Cantor Fitzgerald Upgrades Rezolute to Overweight

FDA Recommends Meeting for Rezolute Drug for Rare Blood Sugar Disorder Despite Missed Endpoints

Rezolute Gets FDA Recommendation For Pre-BLA Meeting Ahead Of Ersodetug BLA Submission For Congenital Hyperinsulinism Treatment.

Lake Street Initiates Coverage On Rezolute with Buy Rating, Announces Price Target of $9

This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Craig-Hallum Upgrades Rezolute to Buy, Raises Price Target to $7

5 Stock Picks Last Week From Wall Street's Most Accurate Analysts

HC Wainwright & Co. Maintains Buy on Rezolute, Raises Price Target to $10